Trilogy Global Advisors’s Gilead Sciences GILD Stock Holding History

Trilogy Global Advisors’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-334,037	Closed	-$23.6M	–	42
2017 Q2	$23.6M	Sell	334,037 -25,105	-7%	-$1.67M	0.79%	44
2017 Q1	$24.4M	Sell	359,142 -21,143	-6%	-$1.49M	0.82%	45
2016 Q4	$27.2M	Sell	380,285 -12,045	-3%	-$895K	0.91%	38
2016 Q3	$31M	Buy	392,330 +8,203	+2%	+$666K	1.03%	30
2016 Q2	$32M	Sell	384,127 -33,553	-8%	-$2.98M	0.99%	38
2016 Q1	$38.4M	Sell	417,680 -45,524	-10%	-$4.11M	1.06%	37
2015 Q4	$46.9M	Sell	463,204 -20,475	-4%	-$2.13M	1.22%	35
2015 Q3	$47.5M	Sell	483,679 -104,520	-18%	-$11.6M	1.28%	31
2015 Q2	$68.9M	Buy	588,199 +148,829	+34%	+$16.3M	1.43%	27
2015 Q1	$43.1M	Buy	+439,370	New	+$44.6M	0.93%	42

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Parnassus Investments San Francisco, California $34.1B AUM 20.22% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Trilogy Global Advisors's GILD Position: Q3 2017 in Review

Trilogy Global Advisors sold out of Gilead Sciences (GILD) in Q3 2017, closing a stake of 334,037 shares — an estimated $23.6M sold.

Trilogy Global Advisors first reported a position in GILD in Q1 2015 and held it in 10 quarters. The position peaked at $68.9M in Q2 2015. 1,503 funds tracked by Wall St. Rank hold GILD as of Q3 2017.

Trilogy Global Advisors reported no remaining Gilead Sciences position as of Q3 2017 after selling out during the quarter.
Trilogy Global Advisors sold 334,037 Gilead Sciences shares in Q3 2017, an estimated $23.6M.
Trilogy Global Advisors first reported a position in Gilead Sciences in Q1 2015 and held it in 10 quarters.
Trilogy Global Advisors's Gilead Sciences position peaked at $68.9M in Q2 2015.
1,503 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2017.

Based on Trilogy Global Advisors's 13F filing for Q3 2017, filed 13 Nov 2017.